Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 7 (July)

1. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.
   J Clin Oncol, 25(19): 2709-18. [Abstract] [Full-text]
2. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.
   Int J Cancer, 121(4): 791-5. [Abstract] [Full-text]
3. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro.
   Int J Cancer, 121(4): 724-33. [Abstract] [Full-text]
4. Patterns in information strategies used by older men to understand and deal with prostate cancer: an application of the modélisation qualitative research design.
   Int J Nurs Stud, 44(6): 961-72. [Abstract] [Full-text]
5. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
   J Cell Physiol, 212(3): 572-8. [Abstract] [Full-text]
6. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.
   Int J Cancer, 121(5): 999-1008. [Abstract] [Full-text]
7. Prostate carcinoma cells selected by long-term exposure to reduced oxygen tension show remarkable biochemical plasticity via modulation of superoxide, HIF-1alpha levels, and energy metabolism.
   J Cell Physiol, 212(3): 744-52. [Abstract] [Full-text]
8. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism.
   Int J Cancer, 121(5): 984-91. [Abstract] [Full-text]
9. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
   J Natl Cancer Inst, 99(13): 1025-35. [Abstract] [Full-text]
10. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    J Surg Oncol, 96(1): 54-61. [Abstract] [Full-text]
11. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells.
    Eur J Pharm Biopharm, 67(1): 1-8. [Abstract] [Full-text]
12. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
    Cancer Res, 67(13): 6368-75. [Abstract] [Full-text]
13. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
    Cancer Res, 67(13): 6263-9. [Abstract] [Full-text]
14. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
    Cancer Res, 67(13): 6192-203. [Abstract] [Full-text]
15. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
    Cancer Res, 67(13): 6183-91. [Abstract] [Full-text]
16. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
    Cancer Res, 67(13): 6155-62. [Abstract] [Full-text]
17. MicroRNA expression profiling in prostate cancer.
    Cancer Res, 67(13): 6130-5. [Abstract] [Full-text]
18. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Cancer Res, 67(13): 6083-91. [Abstract] [Full-text]
19. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.
    Cancer Res, 67(13): 6022-5. [Abstract] [Full-text]
20. Prostate cancer testing following a negative prostate biopsy: over testing the elderly.
    J Gen Intern Med, 22(8): 1139-43. [Abstract] [Full-text]
21. Reconsidering the use of the International Index of Erectile Function questionnaire in evaluating the preoperative erectile function status of patients undergoing radical prostatectomy.
    BJU Int, 100(2): 368-70. [Abstract] [Full-text]
22. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
    BJU Int, 100(2): 362-7. [Abstract] [Full-text]
23. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    BJU Int, 100(2): 315-9. [Abstract] [Full-text]
24. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer.
    BJU Int, 100(2): 303-9. [Abstract] [Full-text]
25. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    BJU Int, 100(2): 310-4. [Abstract] [Full-text]
26. Cryotherapy for the prostate: an in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system.
    BJU Int, 100(2): 295-302. [Abstract] [Full-text]
27. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    BJU Int, 100(2): 274-80. [Abstract] [Full-text]
28. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
    J Pathol, 212(4): 386-94. [Abstract] [Full-text]
29. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
    J Pathol, 212(4): 395-401. [Abstract] [Full-text]
30. Phyto-oestrogens and risk of prostate cancer in Scottish men.
    Br J Nutr, 98(2): 388-96. [Abstract] [Full-text]
31. The prostate needle biopsy gun: busting a myth.
    J Urol, 178(2): 683-5. [Abstract] [Full-text]
32. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition.
    J Urol, 178(2): 692-6. [Abstract] [Full-text]
33. Erectile function outcome reporting after clinically localized prostate cancer treatment.
    J Urol, 178(2): 597-601. [Abstract] [Full-text]
34. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function.
    J Urol, 178(2): 602-7. [Abstract] [Full-text]
35. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
    J Urol, 178(2): 529-34; discussion 534. [Abstract] [Full-text]
36. Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
    J Urol, 178(2): 613-6. [Abstract] [Full-text]
37. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    J Urol, 178(2): 473-7; discussion 477. [Abstract] [Full-text]
38. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate.
    J Urol, 178(2): 483-7; discussion 487. [Abstract] [Full-text]
39. A direct comparison of robotic assisted versus pure laparoscopic radical prostatectomy: a single institution experience.
    J Urol, 178(2): 478-82. [Abstract] [Full-text]
40. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    J Urol, 178(2): 493-9; discussion 499. [Abstract] [Full-text]
41. Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.
    J Urol, 178(2): 464-8; discussion 468. [Abstract] [Full-text]
42. Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy.
    J Urol, 178(2): 488-92; discussion 492. [Abstract] [Full-text]
43. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    J Urol, 178(2): 459-63; discussion 463. [Abstract] [Full-text]
44. Effect of intraprostatic local anesthesia during transrectal ultrasound guided prostate biopsy: comparison of 3 methods in a randomized, double-blind, placebo controlled trial.
    J Urol, 178(2): 469-72; discussion 472. [Abstract] [Full-text]
45. Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey.
    Am J Epidemiol, 166(3): 280-8. [Abstract] [Full-text]
46. Reduced neutron production through use of a flattening-filter-free accelerator.
    Int J Radiat Oncol Biol Phys, 68(4): 1260-4. [Abstract] [Full-text]
47. Quantifying appropriate PTV setup margins: analysis of patient setup fidelity and intrafraction motion using post-treatment megavoltage computed tomography scans.
    Int J Radiat Oncol Biol Phys, 68(4): 1222-8. [Abstract] [Full-text]
48. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
    Int J Radiat Oncol Biol Phys, 68(4): 1161-8. [Abstract] [Full-text]
49. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
    Int J Radiat Oncol Biol Phys, 68(4): 1151-60. [Abstract] [Full-text]
50. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations.
    Int J Radiat Oncol Biol Phys, 68(4): 1065-71. [Abstract] [Full-text]
51. Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking.
    Int J Radiat Oncol Biol Phys, 68(4): 1199-206. [Abstract] [Full-text]
52. Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard.
    Int J Radiat Oncol Biol Phys, 68(4): 1190-8. [Abstract] [Full-text]
53. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(4): 1059-64. [Abstract] [Full-text]
54. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(4): 1053-8. [Abstract] [Full-text]
55. Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.
    J Clin Oncol, 25(21): 3096-100. [Abstract] [Full-text]
56. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
    J Clin Oncol, 25(21): 3082-9. [Abstract] [Full-text]
57. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    J Clin Oncol, 25(21): 3076-81. [Abstract] [Full-text]
58. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Hum Pathol, 38(8): 1207-11. [Abstract] [Full-text]
59. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.
    AJR Am J Roentgenol, 189(2): 323-8. [Abstract] [Full-text]
60. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCaP progression model.
    J Cell Physiol, 213(1): 261-8. [Abstract] [Full-text]
61. A common genetic risk factor for colorectal and prostate cancer.
    Nat Genet, 39(8): 954-6. [Abstract] [Full-text]
62. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
    Nat Genet, 39(8): 977-83. [Abstract] [Full-text]
63. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells.
    J Biol Chem, 282(31): 22651-61. [Abstract] [Full-text]
64. My approach to intraductal lesions of the prostate gland.
    J Clin Pathol, 60(8): 856-65. [Abstract] [Full-text]
65. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Int J Cancer, 121(7): 1424-32. [Abstract] [Full-text]
66. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.
    Int J Cancer, 121(7): 1571-8. [Abstract] [Full-text]
67. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
    J Clin Oncol, 25(22): 3281-7. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.